What is the recommended modified FOLFIRINOX dosing regimen for patients with rectal cancer undergoing concurrent chemoradiotherapy and for pancreatic cancer?

Modified FOLFIRINOX Dosing for Rectal Cancer and Pancreatic Cancer

For rectal cancer concurrent chemoradiotherapy (CCRT), modified FOLFIRINOX is NOT a standard regimen—use capecitabine 825 mg/m² twice daily or continuous infusion 5-FU 225 mg/m²/day during radiotherapy instead. For pancreatic cancer, modified FOLFIRINOX consists of oxaliplatin 85 mg/m², irinotecan 150-180 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m² over 46 hours, repeated every 2 weeks.

Rectal Cancer CCRT Regimens

The most recent guidelines clearly define standard concurrent chemoradiotherapy options for rectal cancer, and modified FOLFIRINOX is not among them 1.

Standard CCRT Options for Rectal Cancer:

• Radiotherapy + Capecitabine: 825 mg/m² twice daily, 5 days per week during radiotherapy 1
• Radiotherapy + 5-FU Continuous Infusion: 225 mg/m²/day continuously during radiotherapy, 5 days per week 1
• Radiotherapy + Irinotecan + Capecitabine (for selected patients): Irinotecan 80 mg/m² weekly (for UGT1A111) or 65 mg/m² weekly (for UGT1A1128) with capecitabine 625 mg/m² twice daily 1

Total Neoadjuvant Therapy (TNT) for Rectal Cancer:

When modified FOLFIRINOX IS used in rectal cancer, it's administered as induction or consolidation chemotherapy in a total neoadjuvant therapy approach—not as concurrent chemoradiotherapy. The PRODIGE-23 trial demonstrated superior outcomes with this strategy 2, 3.

Modified FOLFIRINOX for TNT in rectal cancer:

• Oxaliplatin 85 mg/m² IV over 2 hours, day 1
• Irinotecan 180 mg/m² IV over 90 minutes, day 1
• L-leucovorin 200 mg/m² IV over 2 hours, day 1
• Fluorouracil 2400 mg/m² IV continuous infusion over 46 hours, days 1-3
• Repeat every 14 days for 6 cycles 2, 3

This is followed by standard chemoradiotherapy (capecitabine 800 mg/m² twice daily with 50 Gy radiotherapy), then surgery, then adjuvant chemotherapy 2, 3. The 7-year overall survival with this approach was 81.9% versus 76.1% with standard chemoradiotherapy alone 2.

Pancreatic Cancer Modified FOLFIRINOX Dosing

For metastatic or locally advanced pancreatic cancer in fit patients (ECOG PS 0-1, age ≤75 years, bilirubin ≤1.5× ULN), modified FOLFIRINOX is a first-line standard of care 4, 5.

Standard Modified FOLFIRINOX Regimen:

• Oxaliplatin: 85 mg/m² IV over 2 hours, day 1
• Irinotecan: 150-180 mg/m² IV over 90 minutes, day 1
• Leucovorin: 400 mg/m² IV over 2 hours, day 1 (or L-leucovorin 200 mg/m²)
• Fluorouracil: 2400 mg/m² IV continuous infusion over 46 hours starting day 1
• Repeat every 14 days 6, 7

Key Modifications from Original FOLFIRINOX:

The "modified" version typically omits the 5-FU bolus (400 mg/m²) that was in the original FOLFIRINOX regimen, reducing toxicity while maintaining efficacy 6. Some protocols also reduce irinotecan from 180 mg/m² to 150 mg/m² after safety analyses 6.

Adjuvant Setting for Resected Pancreatic Cancer:

Modified FOLFIRINOX for 24 weeks (12 cycles) demonstrated superior disease-free survival (21.6 vs 12.8 months) and overall survival (54.4 vs 35.0 months) compared to gemcitabine in the adjuvant setting 6.

Critical Dosing Considerations

For Pancreatic Cancer:

• Patient selection is crucial: Only use in patients with ECOG PS 0-1, adequate organ function, and bilirubin ≤1.5× ULN 4, 5
• Toxicity profile: Grade 3-4 adverse events occur in approximately 76% of patients, with neutropenia (38%), diarrhea (25%), and peripheral neuropathy being most common 6
• Primary G-CSF prophylaxis should be considered given high neutropenia rates 8
• Dose reductions occur in approximately 78% of patients in real-world practice 8

Common Pitfall:

Do not confuse the TNT approach for rectal cancer with concurrent chemoradiotherapy. Modified FOLFIRINOX in rectal cancer is given as systemic chemotherapy BEFORE or AFTER chemoradiotherapy, never concurrently with radiation. The concurrent portion uses single-agent fluoropyrimidines 1, 2, 3.

Recent Evidence Note:

A 2025 Japanese trial (GENERATE) showed that modified FOLFIRINOX did NOT demonstrate superiority over nab-paclitaxel + gemcitabine in metastatic pancreatic cancer (median OS 14.0 vs 17.1 months), suggesting nab-paclitaxel + gemcitabine remains a valid alternative, particularly in populations with higher fluoropyrimidine toxicity 9.